Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HX008 plus gemcitabine and cisplatin as first-line treatment for metastatic triple-negative breast cancer
CTR20191353Phase 2Completed
- Sponsor
- Taizhou Hanzhong Biomedical
- Start
- Jul 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of pucotenlimab in triple-negative breast cancer (TNBC), sponsored by Taizhou Hanzhong Biomedical. Started Jul 2019; status: completed.
02
Drugs
pucotenlimab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on CTR20191353.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20191353.